Pages that link to "Q35850389"
Jump to navigation
Jump to search
The following pages link to MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR (Q35850389):
Displayed 39 items.
- Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions (Q26795767) (← links)
- Molecular Testing of Brain Tumor (Q33729693) (← links)
- Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). (Q34478948) (← links)
- Altered expression of MGMT in high-grade gliomas results from the combined effect of epigenetic and genetic aberrations (Q34625644) (← links)
- Genome-wide methylation analyses in glioblastoma multiforme (Q35107175) (← links)
- HMGA2 expression pattern and TERT mutations in tumors of the vulva (Q35605755) (← links)
- MGMT testing allows for personalised therapy in the temozolomide era. (Q35827916) (← links)
- DNA methylation analysis of benign and atypical meningiomas: correlation between RUNX3 methylation and WHO grade. (Q35946963) (← links)
- The Prognostic Value of Pyrosequencing-Detected MGMT Promoter Hypermethylation in Newly Diagnosed Patients with Glioblastoma. (Q35992345) (← links)
- O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas (Q36288503) (← links)
- Advances in the management of glioblastoma: the role of temozolomide and MGMT testing (Q36500074) (← links)
- A novel truncated form of HMGA2 in tumors of the ovaries (Q37106836) (← links)
- Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients (Q37526270) (← links)
- MGMT testing for glioma in clinical laboratories: discordance with methylation analyses prevents the implementation of routine immunohistochemistry (Q38044236) (← links)
- Assessing MGMT methylation status and its current impact on treatment in glioblastoma. (Q38317424) (← links)
- DNA hypermethylation in prostate cancer is a consequence of aberrant epithelial differentiation and hyperproliferation. (Q38642046) (← links)
- Prognostic value of O-6-methylguanine-DNA methyltransferase (MGMT) protein expression in glioblastoma excluding nontumour cells from the analysis. (Q38675705) (← links)
- Experimental factors affecting the robustness of DNA methylation analysis (Q38743551) (← links)
- Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma. (Q39876681) (← links)
- Protein sensing in living cells by molecular rotor-based fluorescence-switchable chemical probes (Q41045107) (← links)
- The methylation of a panel of genes differentiates low-grade from high-grade gliomas. (Q41618968) (← links)
- Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. (Q41870675) (← links)
- MGMT promoter methylation in non-neoplastic brain (Q44440342) (← links)
- Alu hypomethylation and MGMT hypermethylation in serum as biomarkers of glioma (Q47110506) (← links)
- A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016. (Q47160563) (← links)
- Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients. (Q47804454) (← links)
- Prognosis of glioblastoma with faint MGMT methylation-specific PCR product (Q48137109) (← links)
- Details matter: the role of genomic location and assay standardization in DNA methylation analyses. (Q50434839) (← links)
- Multiregional radiomics features from multiparametric MRI for prediction of MGMT methylation status in glioblastoma multiforme: A multicentre study. (Q52643306) (← links)
- Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma. (Q55451515) (← links)
- Gene Promoter Methylation Status - Assessment of Two Pyrosequencing Kits and Three Methylation-specific PCR Methods for their Predictive Capacity in Glioblastomas (Q57786867) (← links)
- The influence of DNA degradation in formalin-fixed, paraffin-embedded (FFPE) tissue on locus-specific methylation assessment by MS-HRM (Q58212980) (← links)
- Pyrosequencing Analysis of Promoter Methylation in Meningioma (Q58766022) (← links)
- Methylation in host and viral genes as marker of aggressiveness in cervical lesions: Analysis in 543 unscreened women (Q59353450) (← links)
- The Impact of Promoter Methylation and Temozolomide Treatment in Serbian Patients with Primary Glioblastoma (Q64249903) (← links)
- Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas. (Q64930362) (← links)
- Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma (Q89559170) (← links)
- DNA Methylation Cancer Biomarkers: Translation to the Clinic (Q91708347) (← links)
- Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients (Q92322332) (← links)